Centessa Pharmaceuticals CFO's Equity Disposition Following Eli Lilly Acquisition

This Form 4 filing reports the disposition of equity interests by John J. Crowley, Chief Financial Officer of Centessa Pharmaceuticals plc, following the company's acquisition by Eli Lilly and Company. On June 24, 2026, Eli Lilly completed its acquisition of Centessa through a scheme of arrangement, with shareholders receiving $38.00 per share in cash plus contingent value rights worth up to $9.00 per share. Crowley disposed of 45,000 ordinary shares and three tranches of share options totaling 1,031,000 underlying shares. The share options had exercise prices ranging from $8.80 to $25.19 per share. All equity interests were automatically converted to cash and CVRs at the effective time of the acquisition, resulting in Crowley holding zero shares and options post-transaction. The filing documents the automatic conversion of equity awards as part of the acquisition transaction.